FibroGen Inc. Expected to Post FY2016 Earnings of ($1.15) Per Share (FGEN)
FibroGen Inc. (NASDAQ:FGEN) – Research analysts at Leerink Swann issued their FY2016 earnings per share (EPS) estimates for shares of FibroGen in a research note issued on Wednesday. Leerink Swann analyst G. Porges forecasts that the firm will earn ($1.15) per share for the year. Leerink Swann currently has a “Buy” rating and a $52.00 target price on the stock. Leerink Swann also issued estimates for FibroGen’s Q4 2016 earnings at ($0.70) EPS, FY2017 earnings at ($2.42) EPS, FY2018 earnings at $0.39 EPS, FY2019 earnings at $1.54 EPS and FY2020 earnings at $3.46 EPS.
FibroGen (NASDAQ:FGEN) last issued its quarterly earnings results on Tuesday, November 8th. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.21. FibroGen had a negative net margin of 45.93% and a negative return on equity of 40.38%. The business had revenue of $30.10 million for the quarter, compared to analyst estimates of $24.30 million.
A number of other research analysts also recently commented on the stock. Credit Suisse Group AG reiterated a “buy” rating and set a $37.00 price objective on shares of FibroGen in a research note on Tuesday, August 9th. Zacks Investment Research upgraded shares of FibroGen from a “hold” rating to a “buy” rating and set a $25.00 price objective on the stock in a research note on Friday.
FibroGen (NASDAQ:FGEN) opened at 22.55 on Friday. The stock’s 50 day moving average is $18.74 and its 200-day moving average is $18.24. FibroGen has a 52 week low of $14.38 and a 52 week high of $31.90. The firm’s market capitalization is $1.42 billion.
In other news, CEO Thomas B. Neff sold 37,798 shares of the firm’s stock in a transaction dated Tuesday, November 1st. The shares were sold at an average price of $16.76, for a total value of $633,494.48. Following the transaction, the chief executive officer now directly owns 3,350,871 shares in the company, valued at approximately $56,160,597.96. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Thomas B. Neff sold 18,899 shares of the firm’s stock in a transaction dated Monday, October 3rd. The stock was sold at an average price of $20.55, for a total transaction of $388,374.45. Following the completion of the transaction, the chief executive officer now owns 3,370,103 shares in the company, valued at $69,255,616.65. The disclosure for this sale can be found here. 14.90% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Fund Advisors increased its position in FibroGen by 2.7% in the first quarter. BlackRock Fund Advisors now owns 1,956,290 shares of the biopharmaceutical company’s stock worth $41,649,000 after buying an additional 51,957 shares during the last quarter. State Street Corp increased its position in FibroGen by 15.1% in the first quarter. State Street Corp now owns 1,330,809 shares of the biopharmaceutical company’s stock worth $28,335,000 after buying an additional 174,369 shares during the last quarter. TIAA CREF Investment Management LLC increased its position in FibroGen by 2.2% in the first quarter. TIAA CREF Investment Management LLC now owns 237,645 shares of the biopharmaceutical company’s stock worth $5,059,000 after buying an additional 5,063 shares during the last quarter. Capital Fund Management S.A. acquired a new position in FibroGen during the second quarter worth about $550,000. Finally, Fox Run Management L.L.C. acquired a new position in FibroGen during the second quarter worth about $176,000. Institutional investors own 49.76% of the company’s stock.
FibroGen, Inc is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.
Receive News & Stock Ratings for FibroGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc. and related stocks with our FREE daily email newsletter.